The biotech firm reported a GAAP loss per share of $0.32, wider than expected, as cash reserves declined quarter-over-quarter.
Camp4 Therapeutics posted a first-quarter GAAP loss per share of $0.32, missing estimates by $0.11. The wider-than-expected loss reflects ongoing R&D investments and operational costs.
Cash and cash equivalents fell to $99.2M as of March 31, 2026, down from $109.5M at the end of 2025. The company stated its current reserves will fund planned activities into 2028.
Shares showed limited immediate reaction in after-hours trading, as investors weighed the earnings miss against long-term funding runway.